Abstract
Left ventricular (LV) diastolic dysfunction is an important contributor to many different cardiovascular diseases. LV diastolic dysfunction can manifest itself as slow LV relaxation, slow LV filling or high diastolic LV stiffness. Diastolic abnormalities have been described in the senescent heart, in heart failure with preserved ejection fraction (HFPEF), in diabetic cardiomyopathy, in aortic valve stenosis (AVS), in hypertrophic cardiomyopathy (HCM), as well as in Fabry disease (FD), however, exact cellular and molecular alterations behind the diastolic deterioration in these diseases are not yet completely characterized. Several studies thoroughly investigated altered cardiomyocyte function, changes of contractile myofilaments, extracellular collagen deposition and advanced glycation end products (AGEs) cross-linking in the background of diastolic dysfunction. These clinical and experimental data suggest that underlying mechanisms of LV diastolic dysfunction are divergent in different cardiac pathologies, therefore the present review aims to summarize mechanisms at the cellular level of diastolic abnormalities in various cardiovascular diseases.
Keywords: Cardiomyocytes, contractile dysfunction, diabetes mellitus, diastole, fibrosis, human heart
Current Pharmaceutical Biotechnology
Title:Cellular Mechanisms for Diastolic Dysfunction in the Human Heart
Volume: 13 Issue: 13
Author(s): Daniel Czuriga, Walter J. Paulus, Istvan Czuriga, Istvan Edes, Zoltan Papp and Attila Borbely
Affiliation:
Keywords: Cardiomyocytes, contractile dysfunction, diabetes mellitus, diastole, fibrosis, human heart
Abstract: Left ventricular (LV) diastolic dysfunction is an important contributor to many different cardiovascular diseases. LV diastolic dysfunction can manifest itself as slow LV relaxation, slow LV filling or high diastolic LV stiffness. Diastolic abnormalities have been described in the senescent heart, in heart failure with preserved ejection fraction (HFPEF), in diabetic cardiomyopathy, in aortic valve stenosis (AVS), in hypertrophic cardiomyopathy (HCM), as well as in Fabry disease (FD), however, exact cellular and molecular alterations behind the diastolic deterioration in these diseases are not yet completely characterized. Several studies thoroughly investigated altered cardiomyocyte function, changes of contractile myofilaments, extracellular collagen deposition and advanced glycation end products (AGEs) cross-linking in the background of diastolic dysfunction. These clinical and experimental data suggest that underlying mechanisms of LV diastolic dysfunction are divergent in different cardiac pathologies, therefore the present review aims to summarize mechanisms at the cellular level of diastolic abnormalities in various cardiovascular diseases.
Export Options
About this article
Cite this article as:
Czuriga Daniel, J. Paulus Walter, Czuriga Istvan, Edes Istvan, Papp Zoltan and Borbely Attila, Cellular Mechanisms for Diastolic Dysfunction in the Human Heart, Current Pharmaceutical Biotechnology 2012; 13 (13) . https://dx.doi.org/10.2174/1389201011208062532
DOI https://dx.doi.org/10.2174/1389201011208062532 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adverse Effects of Cigarette Smoke and Induction of Oxidative Stress in Cardiomyocytes and Vascular Endothelium
Current Pharmaceutical Design Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Interest of Antioxidant Agents in Parasitic Diseases. The Case Study of Coumarins
Current Topics in Medicinal Chemistry Chlorpyrifos with Age-Dependent Effects in Cardiac Tissue of Male Rats
Current Molecular Pharmacology Electrocardiographic Abnormalities in Thalassemia Patients with Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design The Insular Cortex and Takotsubo Cardiomyopathy
Current Pharmaceutical Design Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Blockade of Apoptosis by ACE Inhibitors and Angiotensin Receptor Antagonists
Current Pharmaceutical Design The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach
Current Diabetes Reviews Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Antidiabetic Potential of Naturally Occurring Sesquiterpenes: A Review
Current Topics in Medicinal Chemistry The Role of iNOS in Chronic Inflammatory Processes In Vivo: Is it Damage-Promoting, Protective, or Active at all?
Current Molecular Medicine Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Targeting Resveratrol to Mitochondria for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Cardiac Stem Cell Regeneration in Metabolic Syndrome
Current Pharmaceutical Design Building A New Treatment For Heart Failure-Transplantation of Induced Pluripotent Stem Cell-derived Cells into the Heart
Current Gene Therapy Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery